TuisAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Vorige sluiting
$27,82
Dagwisseling
$26,87 - $27,74
Jaarwisseling
$23,42 - $62,58
Markkapitalisasie
1,56 mjd USD
Gemiddelde volume
704,96 k
P/V-verhouding
2,33
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 10,73 m | 51,06% |
Bedryfskoste | 51,70 m | 46,43% |
Netto inkomste | -96,52 m | -0,61% |
Netto winsgrens | -899,56 | 33,40% |
Wins per aandeel | -1,74 | -1,16% |
EBITDA | -123,67 m | -17,92% |
Effektiewe belastingkoers | 8,42% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 893,71 m | 15,03% |
Totale bates | 1,66 mjd | 77,48% |
Totale aanspreeklikheid | 122,24 m | -3,06% |
Totale ekwiteit | 1,54 mjd | — |
Uitstaande aandele | 57,30 m | — |
Prys om te bespreek | 1,03 | — |
Opbrengs op bates | -18,09% | — |
Opbrengs op kapitaal | -19,03% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -96,52 m | -0,61% |
Kontant van bedrywe | -133,17 m | -83,71% |
Kontant van beleggings | -49,16 m | -151,47% |
Kontant van finansiering | 4,84 m | 471,66% |
Netto kontantverandering | -177,48 m | -843,48% |
Beskikbare kontantvloei | -108,06 m | -155,48% |
Meer oor
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Gestig
2008
Webwerf
Werknemers
487
